DE60129573D1 - Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat - Google Patents

Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat

Info

Publication number
DE60129573D1
DE60129573D1 DE60129573T DE60129573T DE60129573D1 DE 60129573 D1 DE60129573 D1 DE 60129573D1 DE 60129573 T DE60129573 T DE 60129573T DE 60129573 T DE60129573 T DE 60129573T DE 60129573 D1 DE60129573 D1 DE 60129573D1
Authority
DE
Germany
Prior art keywords
fenofibrate
spray drying
compositions containing
powdered compositions
dosage forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60129573T
Other languages
English (en)
Other versions
DE60129573T2 (de
Inventor
Gary Pace
Awadhesh K Mishra
Robert A Snow
Indu Parikh
H Pol-Henri Dr Guivarc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
Jagotec AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec AG filed Critical Jagotec AG
Application granted granted Critical
Publication of DE60129573D1 publication Critical patent/DE60129573D1/de
Publication of DE60129573T2 publication Critical patent/DE60129573T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60129573T 2000-09-20 2001-04-20 Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat Expired - Lifetime DE60129573T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23418600P 2000-09-20 2000-09-20
US234186P 2000-09-20
US24176100P 2000-10-20 2000-10-20
US241761P 2000-10-20
US27015701P 2001-02-22 2001-02-22
US270157P 2001-02-22
PCT/US2001/012746 WO2002024169A1 (en) 2000-09-20 2001-04-20 Spray drying process and compositions of fenofibrate

Publications (2)

Publication Number Publication Date
DE60129573D1 true DE60129573D1 (de) 2007-09-06
DE60129573T2 DE60129573T2 (de) 2008-04-17

Family

ID=27398528

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60129573T Expired - Lifetime DE60129573T2 (de) 2000-09-20 2001-04-20 Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat

Country Status (9)

Country Link
US (1) US6696084B2 (de)
EP (1) EP1322289B1 (de)
AT (1) ATE367802T1 (de)
AU (2) AU6294501A (de)
CA (1) CA2423335C (de)
DE (1) DE60129573T2 (de)
NZ (1) NZ525306A (de)
TW (1) TWI293877B (de)
WO (1) WO2002024169A1 (de)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US6182712B1 (en) 1997-07-21 2001-02-06 Inhale Therapeutic Systems Power filling apparatus and methods for their use
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
CA2346001C (en) * 1998-10-01 2003-12-30 Elan Pharma International, Limited Controlled release nanoparticulate compositions
EP1133281A1 (de) * 1998-11-20 2001-09-19 RTP Pharma Inc. Dispergierbare mit phospholipid stabilisierte mikropartikel
FR2795961B1 (fr) 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7122376B2 (en) * 2001-11-01 2006-10-17 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
US7049146B2 (en) 2000-11-14 2006-05-23 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
CA2461349C (en) 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
WO2003088951A1 (en) * 2002-04-15 2003-10-30 Eiffel Technologies Limited Formulation of fine particles using liquefied or dense gases
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
NO346970B1 (no) * 2002-05-24 2023-03-20 Alkermes Pharma Ireland Ltd Nanopartikulære fiberformuleringer
EP1531799A1 (de) * 2002-06-10 2005-05-25 Elan Pharma International Limited Pharmazeutische nanopartikel-formulierungen mit hmg-coa-reduktase-inhibitoren ("statine"), neue kombinationen davon sowie herstellung dieser pharmazeutischen zusammensetzungen
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
US20040060265A1 (en) * 2002-06-27 2004-04-01 Nektar Therapeutics Controlling the flow of a powder
WO2004065380A1 (en) 2003-01-14 2004-08-05 Arena Pharmaceuticals Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
WO2004096113A2 (en) 2003-04-28 2004-11-11 Medical Instill Technologies, Inc. Container with valve assembly for filling and dispensing substances, and apparatus and method for filling
US20040241252A1 (en) * 2003-05-29 2004-12-02 Abney Christopher Charles Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same
JP4920410B2 (ja) 2003-07-14 2012-04-18 アリーナ ファーマシューティカルズ， インコーポレイテッド 代謝モジュレーターとしての縮合アリールおよびヘテロアリール誘導体ならびに代謝に関連する障害の予防および治療
US7658944B2 (en) 2003-10-10 2010-02-09 Lifecycle Pharma A/S Solid dosage form comprising a fibrate
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
RU2343905C2 (ru) * 2003-10-10 2009-01-20 Лайфсайкл Фарма А/С Твердые дозированные формы, включающие фибрат и статин
US20050096390A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
ATE428411T1 (de) * 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
BRPI0508111A (pt) * 2004-03-30 2007-07-17 Smithkline Beecham Corp composições farmacêuticas secas por aspersão
US7611630B2 (en) * 2004-03-30 2009-11-03 Bend Research, Inc. Method and device for evaluation of pharmaceutical compositions
US7101585B2 (en) * 2004-04-15 2006-09-05 Solae, Llc Ultra high pressure homogenization process for making a stable protein based acid beverage
US7306562B1 (en) * 2004-04-23 2007-12-11 Medical Software, Llc Medical risk assessment method and program product
GB0411502D0 (en) * 2004-05-22 2004-06-23 Britannia Pharmaceuticals Ltd Pharmaceutical compositions
US7495052B2 (en) * 2004-09-15 2009-02-24 Bausch & Lomb Incorporated Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
US20060057216A1 (en) * 2004-09-15 2006-03-16 Salamone Joseph C Low-obscuration image transmitting particulate ocular therapeutic formulations
US20060057215A1 (en) * 2004-09-15 2006-03-16 Raiche Adrian T Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
CA2582403A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
WO2006037345A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical composition comprising fenofibrate and simvastatin
CA2589537A1 (en) * 2004-12-02 2006-06-08 Stephen Craig Dyar Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
EP1853249A2 (de) * 2005-02-10 2007-11-14 LifeCycle Pharma A/S Stabile pharmazeutische zusammensetzung aus einer fixdosen-kombination von fenofibrat und einem hmg-coa-reductase-hemmer
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
US20060223882A1 (en) * 2005-03-23 2006-10-05 Venkataraman Sundaram Amorphous simvastatin
US20070148233A1 (en) * 2005-12-28 2007-06-28 Lerner E I Pharmaceutical formulations of fenofibrate having improved bioavailability
WO2006107316A1 (en) * 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Improved formulations of fenofibrate containing menthol or peg/poloxamer
MX2007012124A (es) * 2005-03-30 2007-11-21 Teva Pharma Formulaciones mejoradas de fenofibrato.
KR20080004600A (ko) * 2005-04-13 2008-01-09 라이프사이클 파마 에이/에스 피브레이트를 포함하는 정제
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
EP1808162A1 (de) * 2005-11-21 2007-07-18 Teva Pharmaceutical Industries Ltd. Pharmazeutische Formulierung von Atorvastatin
RU2395280C2 (ru) * 2005-11-21 2010-07-27 Тева Фармасьютикл Индастриес Лтд. Фармацевтическая лекарственная форма аторвастатина
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
DE602005014258D1 (de) * 2005-12-28 2009-06-10 Teva Pharma Pharmazeutische Formulierungen mit Fenofibrat mit verbesserter Bioverfügbarkeit
CN101351191A (zh) * 2005-12-28 2009-01-21 特瓦制药工业有限公司 生物利用率改善的非诺贝特药物制剂
EP1905424A3 (de) * 2006-02-02 2008-04-30 Ranbaxy Laboratories Limited Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, die stabilisierte Statin-Partikel enthält
US20090140212A1 (en) * 2006-02-24 2009-06-04 Friedman Joel M Electron Transfer Through Glassy Matrices
ES2683919T3 (es) 2006-04-24 2018-09-28 Medical Instill Technologies, Inc. Dispositivo de liofilización que puede perforarse con una aguja y volverse a sellar, y método relacionado
EP1870649A1 (de) 2006-06-20 2007-12-26 Octapharma AG Gefriertocknung zum Erzielen einer bestimmte Restfeuchte durch beschränkte Desorptionsenergiepegeln.
EP2037888A2 (de) * 2006-06-26 2009-03-25 Mutual Pharmaceutical Company, Inc. Wirkstoffformulierungen sowie verfahren zu ihrer herstellung und verwendung
US7877895B2 (en) 2006-06-26 2011-02-01 Tokyo Electron Limited Substrate processing apparatus
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
US8455662B2 (en) * 2006-07-21 2013-06-04 Novartis Ag Formulations for benzimidazolyl pyridyl ethers
US20100003332A1 (en) * 2006-07-27 2010-01-07 Amorepacific Corporation Process For Preparing Powder Comprising Nanoparticles of Sparingly Soluble Drug
US20080132560A1 (en) * 2006-11-21 2008-06-05 San-Laung Chow Solid dispersion composition
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
US7908765B2 (en) * 2006-12-22 2011-03-22 Collette Nv Continuous granulating and drying apparatus
US20080161594A1 (en) * 2006-12-29 2008-07-03 Industrial Technology Research Institute Method for fabricating nanoparticles containing fenofibrate
US7872560B2 (en) * 2007-03-19 2011-01-18 Abc Taiwan Electronics Corp. Independent planar transformer
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
EP2162120B1 (de) * 2007-06-04 2016-05-04 Bend Research, Inc Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
SI2200588T1 (sl) 2007-09-25 2019-08-30 Solubest Ltd. Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
WO2009073216A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
EP2231169B1 (de) * 2007-12-06 2016-05-04 Bend Research, Inc. Pharmazeutische zusammensetzungen mit nanopartikeln und resuspensionsmaterial
US20090182053A1 (en) * 2007-12-19 2009-07-16 Tong Sun Fenofibric acid amorphous dispersion; method of making; and method of use thereof
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
WO2010111132A2 (en) 2009-03-27 2010-09-30 Bend Research, Inc. Spray-drying process
KR100980749B1 (ko) 2009-12-17 2010-09-07 삼일제약주식회사 페노피브레이트-함유 과립 및 이를 포함하는 약학 조성물
US9084944B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
WO2012031129A2 (en) 2010-09-03 2012-03-08 Bend Research, Inc. Spray-drying apparatus and methods of using the same
PE20131371A1 (es) 2010-09-22 2013-11-25 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este
US9248584B2 (en) 2010-09-24 2016-02-02 Bend Research, Inc. High-temperature spray drying process and apparatus
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
RU2666963C2 (ru) 2012-04-13 2018-09-13 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Агрегированные частицы
US8722083B2 (en) * 2012-06-25 2014-05-13 Mylan, Inc. Fenofibrate formulation
US9439860B2 (en) 2012-06-25 2016-09-13 Mylan, Inc. Fenofibrate formulation
MX2013006332A (es) * 2013-06-05 2014-12-19 Alparis Sa De Cv Composiciones farmaceuticas orales para uso en dislipidemias.
EP2878311A1 (de) * 2013-11-27 2015-06-03 Freund Pharmatec Ltd. Verbesserung der Löslichkeit für hydrophobe Wirkstoffe
US11464741B2 (en) 2014-06-11 2022-10-11 SpecGx LLC Spray dried compositions having different dissolution profiles and processes for their preparation
US9561184B2 (en) 2014-09-19 2017-02-07 Velico Medical, Inc. Methods and systems for multi-stage drying of plasma
PT3212169T (pt) 2014-10-31 2021-05-06 Bend Res Inc Processo para formar domínios ativos dispersos numa matriz
KR20230151072A (ko) 2015-01-06 2023-10-31 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 상태의 치료 방법
CA3002551A1 (en) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
US10627161B2 (en) * 2018-01-24 2020-04-21 King Abdulaziz City for Science and Technology (KACST) Laboratory equipment and method of using the same for drying a starting material to produce nano material
WO2022183281A1 (en) * 2021-03-03 2022-09-09 Mcmaster Christopher R Compounds and treatments for muscular dystrophy
US20220313678A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Spray dried nicotine for inclusion in oral products
US11841189B1 (en) * 2022-09-15 2023-12-12 Velico Medical, Inc. Disposable for a spray drying system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329446A1 (de) 1993-09-01 1995-03-02 Basf Ag Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen
FR2737121B1 (fr) * 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
EP0807431B1 (de) * 1996-05-14 2004-03-24 DSM IP Assets B.V. Herstellungsverfahren für Carotenoid-Zusammensetzungen
RU2186562C2 (ru) * 1996-08-22 2002-08-10 Ресеч Трайангл Фармасьютикалс Лтд. Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
EP1133281A1 (de) * 1998-11-20 2001-09-19 RTP Pharma Inc. Dispergierbare mit phospholipid stabilisierte mikropartikel
DE19858789A1 (de) 1998-12-18 2000-06-21 Bayer Ag Kombination von Cerivastatin und Fibraten

Also Published As

Publication number Publication date
DE60129573T2 (de) 2008-04-17
TWI293877B (en) 2008-03-01
WO2002024169A1 (en) 2002-03-28
EP1322289A1 (de) 2003-07-02
NZ525306A (en) 2004-11-26
ATE367802T1 (de) 2007-08-15
US20020056206A1 (en) 2002-05-16
EP1322289B1 (de) 2007-07-25
AU2001262945B2 (en) 2006-02-02
CA2423335A1 (en) 2002-03-28
AU6294501A (en) 2002-04-02
CA2423335C (en) 2011-03-01
US6696084B2 (en) 2004-02-24

Similar Documents

Publication Publication Date Title
DE60129573D1 (de) Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
KR100757155B1 (ko) 저용량의 엔테카비르 제제 및 그의 용도
EA029890B1 (ru) Фармацевтическая композиция и фармацевтическая композиция в пероральной дозированной лекарственной форме на основе ингибитора dpp iv
CA2874779C (en) Pharmaceutical composition of entecavir and process of manufacturing
MXPA04007427A (es) Formulaciones de azitromicina granuladas por via seca.
JP5674275B2 (ja) 活性成分の放出時間が長い組成物、その調製方法および利用方法
DE69915478D1 (de) Geschmacksmaskierung mittels croscarmellose
HUP0202781A2 (hu) Béta-karbolin szemcsés formája, ezt tartalmazó gyógyszerkészítmények, előállításaik és alkalmazásuk
NO20011211D0 (no) Multippel enhet for kontrollert mateffektuavhengig frigivelse av farmasøytiske preparater og fremgangsmÕter for fremstilling av samme
MY127350A (en) Flash-melt oral dose formulations
MXPA04003346A (es) Formulacion de dosis oral de disolucion instantanea.
CA2435714A1 (en) Fenofibrate tablets
RU2199312C1 (ru) Способ получения лекарственных средств из растительных экстрактов в твердой форме
JPH0225428A (ja) 苦味の軽減方法および苦味軽減組成物
RU2287338C2 (ru) Способ получения таблеток из сухого экстракта зверобоя
Akiladevi et al. A Study on the Effect of disintegrants and Processing Methods on the Physicochemical and In Vitro Release Characteristics of Immediate Release Tablets of Bosentan Monohydrate
KR20080059035A (ko) 쓴 맛을 은폐한 경구 고형 조성물
RU2166942C1 (ru) Фармацевтический состав, обладающий противотуберкулезным действием, и способ его получения
RU2188017C1 (ru) Способ получения таблеток комбинированного препарата триметоприма с сульфаметоксазолом
EP3900708A1 (de) Zaltoprofen enthaltendes arzneimittel mit verzögerter freisetzung
RU2163121C1 (ru) Средство от простуды
AU2006235960B2 (en) Low dose entecavir formulation and use
RU2195286C1 (ru) Твердая лекарственная форма, содержащая глицирам
RU2190403C1 (ru) Фармацевтическая композиция, обладающая антибактериальным действием, и способ ее получения
RU2207128C2 (ru) Диуретическое и гипотензивное средство

Legal Events

Date Code Title Description
8364 No opposition during term of opposition